Stocks Industrials LAB
NASDAQ · IndustrialsStandard Biotools Inc. (LAB)
Standard Biotools Inc. brought in $84.4M of revenue over the twelve months to September 30, 2026, up 35.2% from a year earlier. Net income was $133.1M, a net margin of 157.6%. In fiscal 2025 capital spending exceeded operating cash flow by $82.6M. At September 30, 2026 it held $267.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Standard Biotools Inc.
- Net worth
- Standard Biotools Inc. has a market value (market cap) of $249.7M at the latest share price, and shareholders' equity of $555.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $85.3M (-6.2% year on year), with a net loss of $74.9M.
- Cash flow
- In fiscal 2025 operations used $74.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
What Standard Biotools Inc. does
Standard Biotools Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LAB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $85.3M | -$74.9M | -$0.20 | -$82.6M |
| 2024 | $91M | -$138.9M | -$0.52 | -$151.8M |
| 2023 | $106.3M | -$74.7M | -$0.94 | -$46.1M |
| 2022 | $97.9M | -$190.1M | -$2.43 | -$93.2M |
| 2021 | $130.6M | -$59.2M | -$0.78 | -$57.3M |
| 2020 | $138.1M | -$53M | -$0.74 | -$28.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LAB ranks in Industrials
Latest SEC filings
What Standard Biotools Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 0.9% to $19.4M versus the same quarter last year; diluted EPS $0.03 versus -$0.09.
- November 3, 2026Form 425 filing 425
- November 3, 2026
- October 21, 2026
- October 9, 2026
- October 5, 2026Form 425 filing 425
- October 5, 2026
- September 30, 2026Form 425 filing 425
- September 30, 2026Material agreement8-KStandard BioTools terminated its prior deal and agreed to sell its mass cytometry business to Element Biosystems for $5.5 million in cash.
- September 9, 2026
Insider trades
What the people running Standard Biotools Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $46.9K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Carey Thomas D.Director | Bought | 75,000 | $46.9K |
| August 20, 2026 | Egholm MichaelPresident & CEO, Director | Shares withheld for tax | 97,627 | $65.6K |
| August 20, 2026 | Kim Hanjoon AlexChief Financial Officer | Shares withheld for tax | 28,195 | $18.9K |
| August 20, 2026 | Mackay SeanSVP & Chief Business Officer | Shares withheld for tax | 25,729 | $17.3K |
| August 3, 2026 | Egholm MichaelPresident & CEO, Director | Shares withheld for tax | 362,625 | $314.8K |
| July 23, 2026 | Kim Hanjoon AlexChief Financial Officer | Shares withheld for tax | 202,476 | $181.2K |
| June 20, 2026 | Mackay SeanSVP & Chief Business Officer | Received as pay | 500,000 | - |
| June 18, 2026 | Hibbs Kathy LDirector | Received as pay | 99,116 | - |
Who owns LAB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Eli Casdin13D, may seek influence with 5 related filers | 23.9% | June 9, 2026 |
| Viking Global Investors LP13D, may seek influence with 9 related filers | 15% | June 12, 2026 |
| Mak Capital One LLC13G, passive with 2 related filers | 7.3% | August 14, 2026 |
| MAK Capital Fund LP13G, passive with 2 related filers | 6.7% | May 15, 2026 |
| Long Focus Capital Management, LLC13G, passive with 1 related filers | 6% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 143 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Casdin Capital, LLC | 88,783,856 | 0 |
| Viking Global Investors LP | 58,651,170 | 0 |
| Mak Capital One LLC | 28,813,904 | +2,641,278 |
| Long Focus Capital Management, LLC | 23,500,000 | +7,484,279 |
| Vanguard Capital Management LLC | 12,252,998 | -563,072 |
| BlackRock, Inc. | 8,254,443 | -16,501,641 |
| Hollow Brook Wealth Management LLC | 5,503,381 | -150,000 |
| Neuberger Berman Group LLC | 4,958,620 | +301,035 |
| Qube Research & Technologies Ltd | 4,820,463 | +4,116,056 |
| Royce & Associates LP | 4,525,333 | +1,519,804 |
| Geode Capital Management, LLC | 3,896,574 | -3,392,762 |
| Tikvah Management LLC | 3,551,058 | -94 |
| Millennium Management LLC | 3,512,665 | +1,410,650 |
| Morgan Stanley | 2,831,668 | -55,478 |
| D. E. Shaw & Co., Inc. | 2,818,026 | +2,618,942 |
| Jane Street Group, LLC | 2,514,299 | new |
| Peapod Lane Capital LLC | 2,411,474 | +382,947 |
| Citadel Advisors LLC | 2,348,570 | +1,123,260 |
| Mink Brook Asset Management LLC | 2,190,973 | new |
| Sone Capital Management, LLC | 2,133,631 | +366,850 |
Insiders
10 insiders reported holding 87,083,826 shares in total, about $57.9M at the last price.
| Holder | Shares |
|---|---|
| Casdin Partners Master Fund, L.P.Director, 10% owner | 72,100,00072,100,000 held indirectly |
| Egholm MichaelPresident & CEO, Director | 6,137,704 |
| Casdin EliDirector, 10% owner | 3,053,169 |
| Kim Hanjoon AlexChief Financial Officer | 2,534,859 |
| Mackay SeanSVP & Chief Business Officer | 1,480,823 |
| Cox TroyDirector | 475,702 |
| Carey Thomas D.Director | 419,456 |
| Eloi Fenel MDirector | 335,299 |
| Witney FrankDirector | 309,978 |
| Hibbs Kathy LDirector | 236,836 |
Questions about LAB
What does Standard Biotools Inc. do?
Standard Biotools Inc. is a company in the Industrials sector, listed on NASDAQ as LAB. Its shares trade on NASDAQ under the ticker LAB.
What is Standard Biotools Inc.'s net worth?
Standard Biotools Inc. has a market value (market cap) of $249.7M at the latest share price, and shareholders' equity of $555.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Standard Biotools Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $133.1M on revenue of $84.4M, a net margin of 157.6%.
How much revenue does Standard Biotools Inc. make?
Over the twelve months to September 30, 2026 Standard Biotools Inc. reported revenue of $84.4M. That is 35.2% more than a year earlier.
When did Standard Biotools Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
Similar companies
Compare LAB with
Follow LAB
Get an email when Standard Biotools Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Standard Biotools Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.